Research
Metabolic adaptation
Tirzepatide induced a mean absolute HbA1c reduction across the three doses ranging from 2.3% to 3.0% in East Asian participants with type 2 diabetes.
Tirzepatide is effective in reducing HbA1c levels in East Asian individuals with type 2 diabetes.
StrongSupportsmedium confidence
Across all BMI and age subgroups, mean absolute HbA1c reductions across the three doses ranged from 2.3% to 3.0%.
Why this rating
Based on the phase 3 clinical trial data presented in the abstract.
Source
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( <scp>SURPASS</scp> programme)
Arihiro Kiyosue et al. · Diabetes Obesity and Metabolism · 2022
rctCited 24×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →